Breast Cancer | Specialty

TILs Associated With Survival for Advanced HER2+ Breast Cancer

December 8th 2016

Higher levels of tumor-infiltrating lymphocytes were associated with improvements in overall survival for patients with advanced HER2-positive breast cancer treated with docetaxel, trastuzumab, and pertuzumab in the phase III CLEOPATRA trial.

Veliparib Regimen Nears 80% Response Rate in BRCA+ Breast Cancer

December 8th 2016

Adding the PARP inhibitor veliparib to carboplatin/paclitaxel chemotherapy induced a response rate of 77.8% in patients with advanced BRCA-positive breast cancer.

DNA Repair Defects Emerge as a New Category for Anticancer Therapies

December 2nd 2016

A coordinated network of signaling pathways works to protect the cell from the toxic effects of DNA damage.

It's Time to Move Beyond the Genome in Breast Cancer

December 2nd 2016

Matthew J. Ellis, MB BChir, PhD, FRCP, provides his expertise on the genomics and molecular profiling of breast cancer.

Lead PALOMA-2 Author Says Results Will Boost Global Use of Palbociclib

November 28th 2016

Results from the phase III PALOMA-2 study—which demonstrated a significant progression-free survival advantage with palbociclib (Ibrance) plus letrozole compared with letrozole alone in ER-positive, HER2-negative metastatic breast cancer—were recently published in The New England Journal of Medicine.

Dr. Carey on QOL Changes Seen in Patients With Breast Cancer

November 23rd 2016

Lisa Carey, MD, associate director, Clinical Research, UNC Lineberger Comprehensive Cancer Center, Richardson and Marilyn Jacobs Preyer Distinguished Professorship for Breast Cancer Research, UNC-Chapel Hill, discusses how she has seen various agents impact quality of life (QOL) when used to treat patients with breast cancer.

Dr. Marcom on Impact of FALCON Trial on HR+ Breast Cancer

November 22nd 2016

Paul Kelly Marcom, MD, associate professor of Medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the impact that the FALCON trial findings have had on the field of hormone receptor-positive breast cancer.

I-SPY 2 Paves the Way for Novel HER2-Targeted Agents in Breast Cancer

November 22nd 2016

There are a wide variety of novel agents currently being investigated in the neoadjuvant setting for patients with HER2-positive breast cancer.

Dr. Tripathy on Immunotherapy Potential in HER2-Positive Breast Cancer

November 19th 2016

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the potential role of immunotherapy in the treatment of patients with HER2-positive breast cancer.

Dr. Borgen on Successful Progress in HER2-Positive Breast Cancer

November 17th 2016

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses the successful progress seen in the treatment landscape of HER2-positive breast cancer.

Improved Patient Selection Needed to Advance HER2+ Breast Cancer Care

November 17th 2016

Immunotherapy and chemotherapy are options physicians should not dismiss for patients with HER2-positive breast cancer, according to Lisa Carey, MD, even with the available targeted agents trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine.

Dr. Tripathy on Neoadjuvant Agents for HER2+ Breast Cancer

November 16th 2016

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses agents that are available and in development in the neoadjuvant setting as treatments for patients with HER2-positive breast cancer.

Expert Sheds Light on Efficacy of Dual HER2-Directed Therapy

November 15th 2016

Dual HER2-directed therapy has demonstrated promising efficacy as a treatment approach for patients with breast cancer. Still, there remains a need for further research pertaining to therapies for HER2-positive patients who do do not meet the current criteria for this neoadjuvant regimen.

Novel Antibody-Drug Conjugate Could Become First Targeted Therapy Approved in TNBC

November 15th 2016

Findings from a highly anticipated, randomized, phase II trial could possibly pave the path for the FDA approval of the first targeted therapy for patients with triple-negative breast cancer, explains Linda T. Vahdat, MD.

Dr. Anders on Systemic Agents for Patients With Breast Cancer and Brain Mets

November 15th 2016

Carey Anders, MD, assistant professor for the Department of Medicine, Division of Hematology and Oncology, at UNC-Chapel Hill, UNC Linebarger Comprehensive Cancer Center, discusses systemic agents available and in development for patients with breast cancer who also have brain metastases.

Dr. Richard Finn on What's Next for Palbociclib After PALOMA in Breast Cancer

November 11th 2016

Richard Finn, MD associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses what’s next for palbociclib following the PALOMA trials.

PI3K Inhibitors for HR+ Breast Cancer

November 11th 2016

HER2 Mutations in Breast Cancer

November 11th 2016

Biomarkers for CDK4/6 Inhibitors

November 11th 2016

Progression of HR+ Metastatic Breast Cancer

November 11th 2016